. *)*

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/519,096	12/27/2004	Philippe Msika	065691-0381	065691-0381 9007	
	7590 07/18/2007 LARDNER LLP		EXAMINER		
SUITE 500		·	WESTERBERG, NISSA M		
3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER	
WASHINGTON, DC 2000/	1609				
			MAIL DATE	DELIVERY MODE	
			07/18/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Occurrence	10/519,096	MSIKA ET AL.				
Office Action Summary	Examiner	Art Unit				
•	Nissa M. Westerberg	1609				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti- rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDON!	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on		•				
	- action is non-final.					
<i>'</i>	· -					
closed in accordance with the practice under E	·					
Disposition of Claims						
4)⊠ Claim(s) <u>20 - 33</u> is/are pending in the application	nn					
4a) Of the above claim(s) is/are withdraw						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	·					
8) Claim(s) 20 -33 are subject to restriction and/or	election requirement.					
Application Papers						
	_					
9) The specification is objected to by the Examiner		Evenine.				
10) The drawing(s) filed on is/are: a) acce	•					
Applicant may not request that any objection to the on Replacement drawing sheet(s) including the correction	- · · ·	• •				
11) The oath or declaration is objected to by the Ex		•				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign	nriority under 35 H S C & 110/a)-(d) or (f)				
a) All b) Some * c) None of:	priority direct 55 5.5.5. § 115(a	y-(a) or (i).				
1. Certified copies of the priority documents	have been received.					
3. Copies of the certified copies of the priori	, ,					
application from the International Bureau	-					
* See the attached detailed Office action for a list of		ed.				
·						
Attachment(s)	4) 🔲 Interview Summary	(PTO.413)				
2) Notice of References Cited (P10-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	ate				
B) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal F 6) Other:	atent Application				
Paper No(s)/Mail Date	J) [Julei					

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 20 - 31, drawn to treatment methods involving a composition for promoting slimming and refining the silhouette.

Group II, claim(s) 32 -33, drawn to cosmetic composition of isoflavones and extract of *Sophora japonica* flowers.

- 2. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the composition of group II is only one embodiment of the compositions as listed for the treatment methods of group I.
- 3. If group I is elected, this application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Ingredients of the composition used in the treatment method. Applicant is required to elect a particular formulation of the composition used in the treatment method. The combination of isoflavones, lipolytic agents, liporeducing agents, and

Application/Control Number: 10/519,096

Art Unit: 1609

antifiltration/venotonic agents and presence or absence of extract of *Sophora japonica* flowers should be detailed. Applicant is cautioned that election of a specific compound that does not have specific written basis as filed may be determined to be New Matter.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

4. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: An embodiment of the compositions used in group I is already known (Gorbach, US Patent 6,060,070) in which glycitin, the glycosylated form of glycitein, is used in a composition for the treatment of symptoms associated with aging skin. Therefore, there is not a contribution over the prior art and the claims lack unity.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Art Unit: 1609

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nissa M. Westerberg whose telephone number is (571) 270-3532. The examiner can normally be reached on M - F, 7:30 a.m. - 5 p.m. ET.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisors, Ardin H. Marschel can be reached on (571) 272-0718 or Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/519,096

Art Unit: 1609

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 5

NMW

Cecilia J. Tsang Supervisory Patent Examiner Technology Center 1600